目的 觀察蓯蓉益腎顆粒聯(lián)合鹽酸美金剛片治療帕金森癡呆的臨床效果。方法 選取2016年2月—2017年2月海南省安寧醫(yī)院收治的帕金森癡呆患者90例，隨機(jī)分為對(duì)照組和治療組，每組各45例。對(duì)照組口服鹽酸美金剛片，第1周劑量為5 mg/次，1次/d；第2周劑量為5 mg/次，2次/d；第3周劑量早上服用10 mg/次，晚上服用5 mg/次；從第4周開(kāi)始維持劑量為早晚各服用10 mg/次，2次/d。治療組在對(duì)照組治療基礎(chǔ)上口服蓯蓉益腎顆粒，2 g/次，2次/d。兩組均持續(xù)治療3個(gè)月。觀察兩組的臨床療效，比較兩組治療前后簡(jiǎn)易智能精神狀態(tài)檢查表（MMSE）評(píng)分，日常生活能力量表（ADL）評(píng)分、統(tǒng)一帕金森病評(píng)分量表（UPDRS）評(píng)分、血清重組人帕金森病蛋白7（PARK7）、干擾素-γ（IFN-γ）的變化情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為68.89%、86.67%。兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組定向力評(píng)分、語(yǔ)言能力評(píng)分、計(jì)算力和注意力評(píng)分、記憶力評(píng)分、ADL評(píng)分均顯著高于治療前，UPDRS評(píng)分顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組定向力評(píng)分、語(yǔ)言能力評(píng)分、計(jì)算力和注意力評(píng)分、記憶力評(píng)分、ADL評(píng)分顯著高于對(duì)照組，UPDRS評(píng)分顯著低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清PARK7、IFN-γ水平顯著降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療后，治療組PARK7、IFN-γ水平顯著低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 蓯蓉益腎顆粒聯(lián)合鹽酸美金剛片治療帕金森癡具有較好的臨床療效，可有效提高患者生活質(zhì)量和日常生活能力，改善認(rèn)知功能，降低血清PARK7、IFN-γ水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the efficacy of Congrong Yishen Granules combined with Memantine Hydrochloride Tablets in treatment of parkinson disease with dementia. Methods Patients (90 cases) with parkinson disease with dementia in Anning Hospital of Hainan February 2016 to February 2017 were randomly divided into control (45 cases) and treatment (45 cases) groups. Patients in the control group were po administered with Memantine Hydrochloride Tablets The was 5 mg/time in first week dosage, once daily. The dosage was 5 mg/time in second week, twice daily. In the third week, the dosage was 10 mg/time in the morning and 5 mg/time in the evening. Starting from the fourth week, the maintenance dosage was 10 mg/time, twice daily. Patients in the treatment group were po administered with Congrong Yishen Granules on the basis of the control group, 2 g/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the changes of MMSE score, ADL score, UPDRS score, PARK7, and IFN-γ in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 68.89% and 86.67%, and there were differences between two groups (P < 0.05). After treatment, directional force score, language ability score, computational power and attention score, memory score, and ADL score in two groups were significantly increased, but UPDRS scores were significantly decreased, and there were differences in the same group (P < 0.05). After treatment, directional force score, language ability score, computational power and attention score, memory score, and ADL score in the treatment group were higher than those in the control group, but UPDRS score was lower than that in the control group, and there were differences between two groups (P < 0.05). After treatment, PARK7 and IFN-γ were significantly decreased, and there were differences in the same group (P < 0.05). After treatment, PARK7 and IFN-γ in the treatment group were lower than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Congrong Yishen Granules combined with Memantine Hydrochloride Tablets has significant clinical effect in treatment of parkinson disease with dementia, and can effectively improve life quality, and also can improve cognitive function, and reduce serum PARK7 and IFN-γ, which has a certain clinical application value.